Gujarat Themis Biosyn Ltd · NSE:GUJTHEM
Gujarat Themis Biosyn — Q3 FY2022 Earnings Presentation
29 slides from Gujarat Themis Biosyn's earnings presentation, March 2022
Slide 1: Investor presentation cover letter to stock exchange
REGD. OFFICE & FACTORY : 69/C, GIDC, INDUSTRIAL ESTATE, VAPI - 3% 195. DIST. VALSAD, GUJARAT. INDIA. TEL: 0260-2430027 Email : hrm@gtb1.in.net CIN No.: L24230611981PLC004878 GTB; CS BSECCWPT/ZOQIALTZ 1.4% March, 2022? 10. ESE ”71:193. 900' 715, ‘I’l he Jeercebhm Towerg n, I, p E ‘ 1410101318071 Dear
Slide 2: Result Update Presentation Q3 & 9M FY22
Gujarat Themis Biosyn Limited ' Result Update Presentation Presentatio Q3 & 9M FY22
Slide 3: Disclaimer
: 3 to Click Disclaimer edit Master title style Disclaimer ] 68 This presentation has been prepared by Gujarat Themis Biosyn Limited (the “Company” ”Company” or “GTBL”) ”GTBL”) solely for for information purposes and does not constitute any offer, recommendation or invitation to purchase or subscrib
Slide 4: Table of Contents
(A) Click to editofMaster Table title style Contents 0 Company Overview Business Overview O O Industry Overview Financial Highlights (0 Way Ahead Way Ahead 3
Slide 5: Company Overview
a "I ‘ N5” ~ "" Company Overview >
Slide 6: Among India's few fermentation based intermediate manufacturers
Click Among to editIndia’s Master fewtitle style Fermentation based Intermediate manufacturer GTBL among one of India’s few fermentation based manufacturer in pharmaceutical field State of Art Manufacturing Facility ▪I Incorporated in 1981 as asjoint joint ▪ Plant in Vapi Vapi (Gujarat) sector Compa
Slide 7: Journey So Far
0 Click to edit Master Journey So Fartitle style ] Git-3 ▪I BIFR declared GTBL as sick ▪I Repaid total _ . . . Company . . ▪ Established workln capital working ca Ital Establlsched as as lom.th joint ▪I Dr. Dr. Dinesh Dinesh Patel Patel stepped stepp9d in as loan g p ▪' Production sector Company wit
Slide 8: Expert and Experienced Management Team
Click to edit Master Expert title style Management Team and Experienced Dr. Dinesh Patel Dr. Sachin Patel Chairman Director ▪ Doctorate in Medicinal Chemistry UK. ▪ Member of Royal Society of Chemistry, London, U.K. ▪I Doctorate in Biological chemistry from from Christ's College, ▪ Industrialist hav
Slide 9: Key Strengths
0 to Click Key Stre edit Key ngths title style Master Strengths ] 61% Strong Product Portfolio ▪I Demand side remains strong for product manufactured 01 by GTBL by GTBL ▪I More than decade old products with no replacement for these ▪I Continued to be most accepted and preferred products a Investment
Slide 10: Business Overview
Business Overview
Slide 11: Strong & Niche Product Portfolio - Growing at pace
Click toStrong edit Master & Nichetitle style Portfolio —– Growing at pace Product ] Current Product Portfolio lamyCIn :"A-e_____d—_——;——-\\ Rifamycin ,” Rifamycin Rifamycin Identified and ▪ Identified and working working developing developing fourfour ▪ An intermediate for ▪ An intermediate for S5
Slide 12: Advantages of using Fermentation Process
o 0 to Click Advanta ges of using Advantages edit Master title the Fermentation Process styleUnique Fermentation ] GB Fermentation Process Fermentation Fermentation Broth Solid // Liquid Solid Liquid Lab Lab Filtration separatm" Separation GTBL and GTBL and Fermentation Fermentation Technology Techn
Slide 13: State of Art Manufacturing Facilities at Vapi
Click to editofMaster State title style Art Manufacturing Facilities at Vapi FERMENTATIUN DEI’ANTMfNT . 14; Among very few companies in India with fermentation fermentation capabilities for Intermediates Environment & Sustainable Friendly & Environment Friendly Using Aerobic Process Using Sustainabl
Slide 14: Industry Overview
Industry Overview 7*.—
Slide 15: Pharmaceutical Market - An Overview
Click to edit Master title Pharmaceutical style An Overview Market- 4,.01 Active Pharmaceutical Ingredient Market valued at 4.: North America-expected to dominate Active USD 172.69 Billion in 2018 and expected to reach Global Market O) 02 a: h USD Billion by 263.80 Billion USD 263.80 2025 with by 20
Slide 16: The Indian Pharma Advantage
‘ o M to Click The Indi edit The an Pharma Phatitle Master Indian rma style Adv antage Advantage ] as ▪I Low cost of production & R&D boosts efficiency of Indian pharma companies, leading to competitive exports Cost Efficiency 01 ▪I India’s cost of production is approximately 33 per cent lower than
Slide 17: Q3 & 9M FY22 Financial Highlights
(13 & Q3 &-9M 9M FY22 Financial Highlights \._. M ‘
Slide 18: Q3 FY22 Financial Highlights
Click to Q3edit FY22Master titleHighlights Financial style Revenue (Rs. Cr) 35.05 32.44 27.20 27' 20 24.40 24.40 23. 30 23.30 18.60 Q2 FY21 Q2 FY21 Q3 FY21 Q3 FY21 FY21 Q4 FY21 Q1 FY22 Q2 FY22 Q3 FY22 EBITDA (Rs. Cr) // Margin (%) PAT (Rs. Cr) // Margin (%) 20 20 54.21% 54-21% 51 55% 52. 63% 52.63%
Slide 19: Q3 FY22 Financial Highlights
Click to Q3edit FY22Master titleHighlights Financial style ] Rs. Crs Q3 FY22 Q3 FY21 YoY% Q2 FY22 .__..'n.99m.¢..fr9m.99¢rati9ns.. . . . . . . . . . . . . . . . . . . . . . . . . Income from Operations . . . . . . . . . $.69.. . . . . . . . . . . . . . . . 24:49.. . . . . . . . . . . _ _ _ _ _ _ _ _
Slide 20: 9M FY22 Financial Highlights
Click to 9Medit FY22Master title Highlights Financial style Rs. Crs 9M FY22 9M FY21 YoY% Income from Operations 86.09 67.26 Other Operating Income 0.00 0.00 Total Income from Operations 86.09 67.26 27.99% Cost of Materials Consumed 18.56 14.93 Changes In Inventory (8.17) (8.80) Employee Cost 5.43 5.
Slide 21: Annual Financial Highlights
Annual Financial Highlights ‘
Slide 22: Financial Highlights - FY21 vs FY20
i 0 Financial Click to Highlights edit Master Financial — FY21 vs title style Highlights – FY21 vs FY20 FY20 A a A ’a‘A A a A 6.39% I 6.39% I 26.67% I 713 bps Revenue from Operations EBITDA EBITDA Margin Rs. 90.56 Crore Rs. 40.33 Crore 44.53% A ’a‘ A E A a A I 27.48% 27.48% I 551 bps 551 bps I 27.42
Slide 23: Annual Financial Highlights - FY21
Click to edit Master Annual title Financial style Highlights — – FY21 ] Revenue (Rs. Cr) 85.12 90.56 85.12 35.69 35.69 38-80 38.80 41-05 41.05 FY17 FY18 FY19 FY20 FY21 (%) EBITDA (Rs. Cr) / Margin (%) PAT (Rs. Cr) (%) Margin (%) Cr)// Margin 45 45 44.5% 50% 50% 33 3y 33.3% 40 0 0 40 37.4% 37 4A 454)
Slide 24: Key Ratios
: 3 to Click Key Ratios edit Key Master title style Ratios RoCE(%)* RoA(%[** RoA(%)** 37.0% 70.91% 70.91% \ 34.2% \59.9% 59.9% 42.77% 41.40% 41.40% 204% 20.4% 18.9% 18.9% 19.6? 19.6% — \33-94 0 33.94% § — FY17 FY18 FY19 FY20 FY21 FY17 FY18 FY19 FY20 FY21 RoE(%|*** RoE(%)*** 53.3% 56.1% Vz‘x, 43.2% 3
Slide 25: Annual Financial Highlights - FY21
0 to Click edit Master Annual title Financial style Highlights — – FY21 Rs. Crs FY21 FY20 YoY% '000mefr0m000200005:.. . . . . . . . 9056.. . . . . . . . I . . . . . . . . . . .85-1.2.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Income from Operations 90.56 85.12 Ot0000
Slide 26: Balance Sheet Highlights - As on 30th September 2021
" 3 to Click Balance edit Master Balance title style—– As on 30 Sheet Highlights 30th th September 2021 Rs. Cr. Rs. Cr. Sept 2021 Mar 2021 Sept 2021 Mar 2021 Total Equity & Liabilities Total Total Assets Shareholders Funds 96.65 69.95 Non Current Non Current Assets Assets 37_45 37.46 24,94 24.94 Sha
Slide 27: Way Ahead
Way Ahead
Slide 28: Our Way Ahead
A to Click Our Way edit Our Ahead Master Way Aheadtitle style ] 68 ▪I In process of identifying new products which which have good domestic and export New Product Development & potential ▪I Company working on strategy to to move up the the value value chain by way way of forward forward Forward Inte
Slide 29: Thank You
0 to Click edit You Thank Master title style ] GB For further information, please contact: Company : Investor Relations Advisors : Gujarat Themis Biosyn Limited Bridge Investor Relations Pvt. Ltd. lyer Mr. Sangameshwar Iyer Mr. Amit Sharma - 9867726686 . . . Mr. Rahul Trivedi Trivedi - 9833541841 Sa
Gujarat Themis Biosyn — Q3 FY2022 Earnings Presentation on 6ix